Fernanda Sakamoto, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Aminolevulinic Acid | 10 | 2015 | 150 | 2.500 |
Why?
|
| Photochemotherapy | 10 | 2015 | 832 | 1.990 |
Why?
|
| Photosensitizing Agents | 8 | 2015 | 633 | 1.450 |
Why?
|
| Laser Therapy | 8 | 2023 | 1107 | 1.080 |
Why?
|
| Keratosis, Actinic | 2 | 2015 | 73 | 0.920 |
Why?
|
| Sebaceous Glands | 4 | 2015 | 42 | 0.850 |
Why?
|
| Acne Vulgaris | 4 | 2023 | 351 | 0.720 |
Why?
|
| Occlusive Dressings | 1 | 2019 | 52 | 0.670 |
Why?
|
| Dermatology | 4 | 2023 | 920 | 0.640 |
Why?
|
| Pruritus | 1 | 2019 | 380 | 0.520 |
Why?
|
| Skin | 9 | 2022 | 4520 | 0.460 |
Why?
|
| Lasers, Solid-State | 5 | 2019 | 183 | 0.450 |
Why?
|
| Cicatrix | 3 | 2023 | 799 | 0.420 |
Why?
|
| Polymers | 1 | 2019 | 1631 | 0.400 |
Why?
|
| Neurofibroma | 2 | 2023 | 95 | 0.400 |
Why?
|
| Sebum | 1 | 2011 | 17 | 0.390 |
Why?
|
| Dermatitis, Atopic | 1 | 2019 | 734 | 0.390 |
Why?
|
| Lasers | 3 | 2023 | 952 | 0.390 |
Why?
|
| Hyperthermia, Induced | 1 | 2015 | 417 | 0.390 |
Why?
|
| Administration, Cutaneous | 4 | 2019 | 716 | 0.350 |
Why?
|
| Porphyrins | 2 | 2014 | 354 | 0.300 |
Why?
|
| Neurofibromatosis 1 | 2 | 2023 | 561 | 0.290 |
Why?
|
| Tattooing | 3 | 2013 | 57 | 0.280 |
Why?
|
| Skin Aging | 2 | 2017 | 141 | 0.240 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 2006 | 167 | 0.240 |
Why?
|
| Skin Neoplasms | 5 | 2023 | 5891 | 0.240 |
Why?
|
| Swine | 9 | 2017 | 5996 | 0.220 |
Why?
|
| Pigmentation Disorders | 1 | 2023 | 104 | 0.210 |
Why?
|
| Phototherapy | 2 | 2016 | 369 | 0.210 |
Why?
|
| Lasers, Gas | 3 | 2014 | 101 | 0.210 |
Why?
|
| Neuroma | 1 | 2023 | 138 | 0.190 |
Why?
|
| Temperature | 3 | 2020 | 2237 | 0.180 |
Why?
|
| Pilot Projects | 5 | 2020 | 8730 | 0.170 |
Why?
|
| Decontamination | 1 | 2020 | 73 | 0.170 |
Why?
|
| Hair Removal | 1 | 2019 | 40 | 0.160 |
Why?
|
| Subcutaneous Fat | 2 | 2013 | 402 | 0.160 |
Why?
|
| Photography | 4 | 2021 | 537 | 0.160 |
Why?
|
| Biomedical Technology | 1 | 2020 | 210 | 0.150 |
Why?
|
| Masks | 1 | 2020 | 215 | 0.150 |
Why?
|
| Administration, Topical | 5 | 2015 | 707 | 0.140 |
Why?
|
| Education, Medical, Continuing | 3 | 2016 | 829 | 0.140 |
Why?
|
| Cross-Linking Reagents | 1 | 2019 | 692 | 0.130 |
Why?
|
| Skin Diseases, Vascular | 1 | 2016 | 41 | 0.130 |
Why?
|
| Skin Diseases | 2 | 2016 | 1099 | 0.130 |
Why?
|
| Ultraviolet Rays | 1 | 2020 | 1100 | 0.120 |
Why?
|
| Rhytidoplasty | 1 | 2015 | 72 | 0.120 |
Why?
|
| Biomimetic Materials | 1 | 2016 | 173 | 0.120 |
Why?
|
| Skin Temperature | 1 | 2014 | 96 | 0.120 |
Why?
|
| Blister | 1 | 2014 | 88 | 0.120 |
Why?
|
| Elasticity | 1 | 2016 | 658 | 0.110 |
Why?
|
| Forearm | 1 | 2015 | 428 | 0.110 |
Why?
|
| Erythema | 1 | 2014 | 262 | 0.110 |
Why?
|
| Treatment Outcome | 11 | 2023 | 65409 | 0.100 |
Why?
|
| Wound Healing | 3 | 2022 | 2819 | 0.100 |
Why?
|
| Materials Testing | 1 | 2016 | 871 | 0.100 |
Why?
|
| Pigmentation | 1 | 2013 | 143 | 0.100 |
Why?
|
| Lipectomy | 1 | 2013 | 115 | 0.100 |
Why?
|
| Equipment Design | 1 | 2020 | 3530 | 0.100 |
Why?
|
| Dermoscopy | 1 | 2012 | 72 | 0.100 |
Why?
|
| Injections, Intradermal | 1 | 2011 | 116 | 0.100 |
Why?
|
| Spectrophotometry | 1 | 2011 | 292 | 0.100 |
Why?
|
| Protoporphyrins | 1 | 2011 | 170 | 0.090 |
Why?
|
| Gold | 1 | 2015 | 489 | 0.090 |
Why?
|
| Burns | 1 | 2022 | 1887 | 0.090 |
Why?
|
| Basal Cell Nevus Syndrome | 1 | 2011 | 38 | 0.090 |
Why?
|
| Leg | 1 | 2015 | 1089 | 0.090 |
Why?
|
| Models, Animal | 3 | 2015 | 2126 | 0.080 |
Why?
|
| Tissue Distribution | 2 | 2014 | 2298 | 0.080 |
Why?
|
| Extremities | 1 | 2014 | 870 | 0.080 |
Why?
|
| Sweat Gland Neoplasms | 2 | 1994 | 116 | 0.080 |
Why?
|
| Skin Absorption | 3 | 2015 | 96 | 0.080 |
Why?
|
| Clinical Protocols | 1 | 2014 | 1444 | 0.080 |
Why?
|
| Pain | 3 | 2023 | 5096 | 0.080 |
Why?
|
| Cryosurgery | 1 | 2013 | 477 | 0.080 |
Why?
|
| Primary Prevention | 1 | 2016 | 1189 | 0.080 |
Why?
|
| Microscopy, Fluorescence | 2 | 2014 | 2640 | 0.070 |
Why?
|
| Random Allocation | 1 | 2011 | 2399 | 0.070 |
Why?
|
| Humans | 29 | 2023 | 768451 | 0.070 |
Why?
|
| Carbon | 1 | 2010 | 671 | 0.070 |
Why?
|
| Microscopy, Confocal | 1 | 2012 | 1977 | 0.070 |
Why?
|
| Male | 18 | 2021 | 364781 | 0.070 |
Why?
|
| Monte Carlo Method | 1 | 2011 | 1262 | 0.070 |
Why?
|
| Female | 18 | 2019 | 396943 | 0.070 |
Why?
|
| Foreign Bodies | 1 | 2010 | 403 | 0.070 |
Why?
|
| Apocrine Glands | 1 | 1985 | 32 | 0.060 |
Why?
|
| Sweat Glands | 1 | 1985 | 33 | 0.060 |
Why?
|
| Adult | 11 | 2023 | 223542 | 0.060 |
Why?
|
| Water | 1 | 2011 | 1421 | 0.060 |
Why?
|
| Quality Improvement | 1 | 2020 | 3858 | 0.060 |
Why?
|
| Endemic Diseases | 1 | 2006 | 191 | 0.060 |
Why?
|
| Biomedical Research | 1 | 2020 | 3463 | 0.060 |
Why?
|
| Zidovudine | 1 | 2006 | 625 | 0.060 |
Why?
|
| Middle Aged | 8 | 2019 | 223418 | 0.060 |
Why?
|
| Deoxycholic Acid | 1 | 2023 | 54 | 0.060 |
Why?
|
| Vincristine | 1 | 2006 | 1039 | 0.050 |
Why?
|
| Analysis of Variance | 1 | 2011 | 6242 | 0.050 |
Why?
|
| Animals | 12 | 2017 | 169418 | 0.050 |
Why?
|
| Brazil | 1 | 2006 | 1247 | 0.050 |
Why?
|
| Follow-Up Studies | 4 | 2016 | 39430 | 0.050 |
Why?
|
| Interferon-alpha | 1 | 2006 | 909 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 15965 | 0.050 |
Why?
|
| Sweat Gland Diseases | 1 | 2001 | 12 | 0.050 |
Why?
|
| Prednisone | 1 | 2006 | 1568 | 0.050 |
Why?
|
| Nevus, Blue | 1 | 2001 | 43 | 0.050 |
Why?
|
| Equipment Reuse | 1 | 2020 | 45 | 0.040 |
Why?
|
| Genital Diseases, Male | 1 | 2001 | 84 | 0.040 |
Why?
|
| Scrotum | 1 | 2001 | 117 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2006 | 2224 | 0.040 |
Why?
|
| Carcinoma, Basal Cell | 1 | 1985 | 564 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2015 | 59680 | 0.040 |
Why?
|
| Humidity | 1 | 2020 | 206 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2006 | 2229 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2011 | 10784 | 0.040 |
Why?
|
| DNA, Viral | 1 | 2006 | 2206 | 0.040 |
Why?
|
| Aged | 4 | 2015 | 171520 | 0.040 |
Why?
|
| Faculty | 1 | 2020 | 384 | 0.030 |
Why?
|
| Skin Transplantation | 1 | 2022 | 1097 | 0.030 |
Why?
|
| Ozone | 1 | 2020 | 490 | 0.030 |
Why?
|
| Siloxanes | 1 | 2016 | 28 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2006 | 6091 | 0.030 |
Why?
|
| Engineering | 1 | 2016 | 56 | 0.030 |
Why?
|
| Cysts | 1 | 2001 | 685 | 0.030 |
Why?
|
| Tensile Strength | 1 | 2016 | 335 | 0.030 |
Why?
|
| Wound Closure Techniques | 1 | 2015 | 88 | 0.030 |
Why?
|
| Rejuvenation | 1 | 2015 | 110 | 0.030 |
Why?
|
| Patient Satisfaction | 2 | 2019 | 3484 | 0.030 |
Why?
|
| Time Factors | 2 | 2015 | 40271 | 0.030 |
Why?
|
| Adenoma, Sweat Gland | 1 | 1994 | 17 | 0.030 |
Why?
|
| Microscopy, Electron, Scanning Transmission | 1 | 2012 | 8 | 0.030 |
Why?
|
| Vimentin | 1 | 1994 | 257 | 0.030 |
Why?
|
| Hair Follicle | 1 | 2015 | 219 | 0.030 |
Why?
|
| Young Adult | 1 | 2019 | 60045 | 0.030 |
Why?
|
| Needles | 1 | 2015 | 455 | 0.030 |
Why?
|
| Keratins | 1 | 1994 | 502 | 0.020 |
Why?
|
| Calcinosis | 1 | 2001 | 1485 | 0.020 |
Why?
|
| Glycosaminoglycans | 1 | 1994 | 611 | 0.020 |
Why?
|
| Particle Size | 1 | 2015 | 1654 | 0.020 |
Why?
|
| Color | 1 | 2011 | 297 | 0.020 |
Why?
|
| Sus scrofa | 1 | 2011 | 430 | 0.020 |
Why?
|
| Risk Assessment | 3 | 2016 | 24311 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2013 | 1585 | 0.020 |
Why?
|
| Coloring Agents | 1 | 2011 | 564 | 0.020 |
Why?
|
| Ferric Compounds | 1 | 2010 | 379 | 0.020 |
Why?
|
| Ketotifen | 1 | 1988 | 24 | 0.020 |
Why?
|
| Histamine Release | 1 | 1988 | 134 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2019 | 81834 | 0.020 |
Why?
|
| Cromolyn Sodium | 1 | 1988 | 78 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2006 | 9425 | 0.020 |
Why?
|
| Hair Diseases | 1 | 1988 | 72 | 0.020 |
Why?
|
| Alkanes | 1 | 1987 | 39 | 0.020 |
Why?
|
| Substance P | 1 | 1988 | 334 | 0.020 |
Why?
|
| Microscopy, Electron | 2 | 1988 | 2565 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 8051 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2006 | 11843 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2023 | 54914 | 0.010 |
Why?
|
| Tumor Burden | 1 | 2011 | 1909 | 0.010 |
Why?
|
| Hair | 1 | 1988 | 508 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 20231 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2006 | 13708 | 0.010 |
Why?
|
| Hypersensitivity | 1 | 2011 | 1172 | 0.010 |
Why?
|
| Eccrine Glands | 1 | 2001 | 52 | 0.010 |
Why?
|
| Mast Cells | 1 | 1988 | 1407 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 8559 | 0.010 |
Why?
|
| Proteins | 1 | 1994 | 6008 | 0.010 |
Why?
|
| Drug Delivery Systems | 1 | 2010 | 2238 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2015 | 10358 | 0.010 |
Why?
|
| Melanocytes | 1 | 2001 | 512 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 18388 | 0.010 |
Why?
|
| Prognosis | 1 | 2016 | 30028 | 0.010 |
Why?
|
| Fibroblasts | 1 | 1985 | 4180 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2010 | 14728 | 0.010 |
Why?
|
| Keratan Sulfate | 1 | 1994 | 17 | 0.010 |
Why?
|
| Dermatan Sulfate | 1 | 1994 | 43 | 0.010 |
Why?
|
| Desmin | 1 | 1994 | 99 | 0.010 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 1994 | 127 | 0.010 |
Why?
|
| Chondroitin Sulfates | 1 | 1994 | 174 | 0.010 |
Why?
|
| Chondroitin Sulfate Proteoglycans | 1 | 1994 | 142 | 0.010 |
Why?
|
| S100 Proteins | 1 | 1994 | 217 | 0.010 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 1994 | 560 | 0.010 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 1994 | 848 | 0.000 |
Why?
|
| Tolonium Chloride | 1 | 1988 | 23 | 0.000 |
Why?
|
| p-Methoxy-N-methylphenethylamine | 1 | 1988 | 41 | 0.000 |
Why?
|
| Depression, Chemical | 1 | 1988 | 186 | 0.000 |
Why?
|
| Peritoneal Cavity | 1 | 1988 | 135 | 0.000 |
Why?
|
| Rats, Inbred Strains | 1 | 1988 | 2087 | 0.000 |
Why?
|
| Sulfhydryl Compounds | 1 | 1988 | 298 | 0.000 |
Why?
|
| Actins | 1 | 1994 | 2064 | 0.000 |
Why?
|
| Ear, External | 1 | 1987 | 165 | 0.000 |
Why?
|
| Autoradiography | 1 | 1987 | 732 | 0.000 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1988 | 946 | 0.000 |
Why?
|
| Hyperplasia | 1 | 1987 | 1154 | 0.000 |
Why?
|
| Staining and Labeling | 1 | 1988 | 1083 | 0.000 |
Why?
|
| Rabbits | 1 | 1987 | 4786 | 0.000 |
Why?
|
| Cell Division | 1 | 1987 | 4479 | 0.000 |
Why?
|
| Adolescent | 1 | 2001 | 89168 | 0.000 |
Why?
|
| Rats | 1 | 1988 | 23839 | 0.000 |
Why?
|